Revenue

U.S. Physical Therapy's Q2 earnings show a complex picture. Discover how its strategic partnerships are setting the stage for future growth.

The holding company's stunning profit leap, driven by its chemical and components arms, reveals a story of operational grit and a major turnaround.

The warehouse giant posts another stellar month with 10.7% sales growth, but its nearly 18% surge in digitally-enabled sales reveals a deeper strategy.

As Biofrontera preps its Q2 report, investors weigh record revenue and expanded margins against persistent losses and a critical need for cash flow breakeven.

NuScale Power’s revenue vanished in Q2, but its cash hoard swelled to $1.9B. It’s a high-stakes pivot from design fees to a costly industrial reality.

One Liberty Properties' stellar Q2 results aren't just good numbers; they're proof of a masterfully executed pivot to industrial real estate, a case study in navigating market shifts.

Traeger's revenue is down 17%, but its new Lowe's deal and aggressive cost-cutting signal a bold, risky pivot. Is this the right recipe for growth?

Beyond record revenues, Park-Ohio's Q2 results reveal a strategic pivot, leveraging AI, aerospace, and electrification to forge a less cyclical, high-growth future.

With soaring revenues and a landmark Microsoft AI deal, A10 Networks is redefining its role. Is this the playbook for winning the AI infrastructure wars?

The geospatial intelligence firm hit a key inflection point, converting 259% revenue growth into its first profitable quarter on an operating basis.

The manufactured home builder is crushing estimates not by chasing trends, but by supplying the critical infrastructure for America's data center boom.

The clean-living brand's revenue is down, but profits and confidence are soaring. A deep dive into how strategic cuts are building a more durable company.

Cytek Biosciences raises 2026 guidance on new tech, but rising costs and a wider net loss have investors questioning its path to sustainable profit.

KORU Medical posts record profits, but the real story is its strategic overhaul. We dissect its oncology pivot and digital tech bet for long-term value.

The hormone optimization leader's stock tumbles after Q2 results show a net loss and declining revenue, revealing the prolonged impact of its January recall.

With a new $345 genome and major clinical wins, PacBio pushes boundaries. But can its strategic restructuring and bold R&D overcome mounting financial losses?

The agentic customer platform posts 20% revenue growth and a return to profitability, yet a softer forecast reveals underlying market pressures.

Chime posts a second GAAP profitable quarter, fueled by its premium tier and lending growth, but a surprise CFO exit raises questions about its next chapter.

As its acquisition looms, LiveRamp posts impressive growth and pivots hard into AI, signaling a new era for data collaboration under Publicis Groupe.

Revenues are up, but profits are down. BBSI's latest quarter reveals the hidden costs of a cooling labor market and rising insurance pressures.